Results 31 to 40 of about 126,887 (307)
Journal of Experimental & Clinical Cancer Research, 2021 Immune checkpoint inhibitors provide considerable therapeutic benefit in a range of solid cancers as well as in a subgroup of hematological malignancies.
Allan Relecom +6 more
doaj +1 more source
Vaccines, 2022 A vital function of the immune system is the modulation of an evolving immune response. It is responsible for guarding against a wide variety of pathogens as well as the establishment of memory responses to some future hostile encounters. Simultaneously,
Konstantinos Tsiakos +7 more
doaj +1 more source
PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy [PDF]
, 2017 Pancreatic ductal adenocarcinoma (PDAC) is considered a non‐immunogenic tumor, and immune checkpoint inhibitor monotherapy lacks efficacy in this disease. Radiotherapy (RT) can stimulate the immune system.
Azad, Abul +11 more
core +1 more source
Frontiers in Immunology, 2020 Advances in cancer immunity have promoted a major breakthrough in the field of cancer therapy. This is mainly associated with the successful development of immune checkpoint inhibitors (ICIs) for multiple types of human tumors.
Yuxiao Song +5 more
doaj +1 more source
Immune checkpoint blockade in infectious diseases [PDF]
Nature Reviews Immunology, 2017 The upregulation of immune checkpoint molecules, such as programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte antigen 4 (CTLA4), on immune cells occurs during acute infections, such as malaria, as well as during chronic persistent viral infections, including HIV and hepatitis B virus.
Wykes, MN, Lewin, SR
openaire +3 more sources
NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance [PDF]
, 2019 Lack of proper innate sensing inside tumor microenvironment (TME) limits T cell-targeted immunotherapy. NAD(P)H:quinone oxidoreductase 1 (NQO1) is highly enriched in multiple tumor types and has emerged as a promising target for direct tumor-killing ...
Boothman, David A. +10 more
core +1 more source
Immune checkpoint blockade in ovarian cancer [PDF]
memo - Magazine of European Medical Oncology, 2016 Increased numbers of tumour infiltrating T‑cells have long been associated with a better prognosis in ovarian cancer, which has led to the general assumption of a relevant impact of T‑cellular anti-tumour immunity in this disease. As a consequence of this knowledge, a multitude of immunologic therapies has emerged over the past years.
Weiss, Lukas +3 more
openaire +2 more sources
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
Frontiers in Oncology, 2021 Immunotherapy has emerged as the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and targeted therapy. Immune checkpoint inhibitors are the current superheroes of immunotherapy, unleashing a patient’s own immune cells to ...
Remy Thomas +4 more
doaj +1 more source
Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. [PDF]
, 2016 BackgroundMalignant peripheral nerve sheath tumor (MPNST) is an aggressive sarcoma with few treatment options. Tumor immune state has not been characterized in MPNST, and is important in determining response to immune checkpoint blockade.
Bernthal, Nicholas +11 more
core +2 more sources
Photodynamic Therapy and Immune Checkpoint Blockade† [PDF]
Photochemistry and Photobiology, 2020 AbstractImmune checkpoints including PD‐1 and CTLA‐4 help to regulate the intensity and timeframe of the immune response. Since they become upregulated in cancer and prevent sufficient antitumor immunity, monoclonal antibodies against these checkpoints have shown clinical promise for a range of cancers.
Gwendolyn M. Cramer +3 more
openaire +2 more sources